NCT01000922

A Study Comparing the Pharmacodynamic Properties of Insulin VIAJECT™, Regular Human Insulin, and Insulin Lispro

A Single Center, Randomized, Open-Label, Crossover Study, Comparing the Pharmacodynamic Properties of Insulin VIAJECT™, Regular Human Insulin, and Insulin Lispro Either in Combination With a Basal Insulin Infusion or With Insulin Glargine Relative to a Standardized Meal in Patients With Type 1 Diabetes

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 24 (actual)
• Sponsor: Biodel · Industry
• Sex: All
• Age: 19 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

Evaluation of post-prandial blood glucose excursions after a standardized meal and pre meal injections of individual doses of the study insulins.

Conditions

• Diabetes Mellitus

Interventions

Type	Name	Description
DRUG	Regular Human Insulin	Individual dose of RHI administered subcutaneously
DRUG	Lispro	Individual dose of lispro administered subcutaneously
DRUG	VIAject	Individual dose of VIAject administered subcutaneously
DRUG	VIAject 50%	Individual dose of VIAject 50% administered subcutaneously
DRUG	VIAject/Insulin Glargine	VIAject mixed wiht insulin glargine and administered subcutaneously
DRUG	Insulin Glargine/VIAject	Individual dose of VIAject and Insulin Glargine administered seperately and subcutaneously

Timeline

• Start date: 2006-06-01
• Primary completion: 2008-01-01
• Completion: 2008-01-01
• First posted: 2009-10-23
• Last updated: 2015-07-29

Locations

1 site across 1 country: United States